Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Publication date: Nov 13, 2025

We saw encouraging within-group improvements in fatigue, sleep, and mood, although we did not observe statistically significant differences between people taking NR and those taking a placebo. This suggests that restoring the NAD+ system can restore multiple biological pathways implicated in long COVID including mitochondrial function, inflammation, and cellular repair. These findings suggest that restoring NAD+ remains a promising avenue for recovery and advancing our understanding of how to help individuals affected by long COVID. What is encouraging is that despite variability among patients, we observed consistent signals of improvement with elevation of NAD+ levels. Actual results may differ materially from those suggested by these forward-looking statements. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors.

Concepts Keywords
Diabetes Bioscience
Efficient Controlled
Scientists Covid
Viral Fatigue
Long
Looking
Nad+
Niagen
Nicotinamide
Placebo
Randomized
Sleep
Statements
Supplementation
Symptoms

Semantics

Type Source Name
disease MESH Long COVID
drug DRUGBANK Nadide
drug DRUGBANK Nonoxynol-9
disease MESH depression
disease MESH sleep quality
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH COVID-19
disease MESH infection
disease MESH breathlessness
disease MESH cognitive impairment
disease MESH brain fog
disease MESH anxiety
disease MESH mitochondrial dysfunction
disease MESH oxidative stress
pathway REACTOME Metabolism
disease MESH Cancer
disease MESH inflammation
disease MESH metabolic stress
disease MESH reinfection
disease IDO symptom
disease IDO role
drug DRUGBANK Coenzyme M
disease IDO cell
disease MESH lifestyle
disease IDO quality
drug DRUGBANK Gold
drug DRUGBANK Tropicamide
pathway REACTOME Release

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *